• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    FibroBiologics, Inc. - Common Stock (NQ:FBLG)

    1.100 +0.050 (+4.76%)
    Streaming Delayed Price Updated: 11:16 AM EDT, Jun 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 225,820
    Open 1.050
    Bid (Size) 1.080 (800)
    Ask (Size) 1.110 (200)
    Prev. Close 1.050
    Today's Range 1.020 - 1.140
    52wk Range 0.9523 - 19.80
    Shares Outstanding 38,262,586
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
    From FibroBiologics, Inc.
    Via GlobeNewswire
    News headline image
    EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial ↗
    FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers. 
    Via Benzinga

    Performance

    YTD
    -77.1%
    -77.1%
    1 Month
    -20.3%
    -20.3%
    3 Month
    -85.9%
    -85.9%
    6 Month
    -79.1%
    -79.1%
    1 Year
    -92.8%
    -92.8%

    More News

    Read More
    News headline image
    FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
    From FibroBiologics, Inc.
    Via GlobeNewswire
    News headline image
    FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
    From FibroBiologics, Inc.
    Via GlobeNewswire
    News headline image
    FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
    From FibroBiologics, Inc.
    Via GlobeNewswire
    News headline image
    FibroBiologics CEO Issues Letter to Shareholders
    From FibroBiologics, Inc.
    Via GlobeNewswire
    News headline image
    FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
    From FibroBiologics, Inc.
    Via GlobeNewswire
    News headline image
    FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
    From FibroBiologics, Inc.
    Via GlobeNewswire
    News headline image
    FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
    From FibroBiologics, Inc.
    Via GlobeNewswire
    News headline image
    FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
    From FibroBiologics, Inc.
    Via GlobeNewswire
    News headline image
    FibroBiologics Compliant with All Nasdaq Listing Requirements
    From FibroBiologics, Inc.
    Via GlobeNewswire
    News headline image
    FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
    From FibroBiologics, Inc.
    Via GlobeNewswire
    News headline image
    FibroBiologics Announces Closing of $3 Million Public Offering
    From FibroBiologics, Inc.
    Via GlobeNewswire
    Which stocks are moving before the opening bell on Wednesday? ↗
    Via Chartmill
    News headline image
    FibroBiologics Announces Pricing of $3 Million Public Offering
    From FibroBiologics, Inc.
    Via GlobeNewswire
    Top movers in Tuesday's after hours session ↗
    Via Chartmill
    News headline image
    FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
    From FibroBiologics, Inc.
    Via GlobeNewswire
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    Which stocks are experiencing notable movement on Tuesday? ↗
    Via Chartmill
    The market is filled with gapping stocks in Tuesday's session. ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Via Chartmill
    News headline image
    FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
    From FibroBiologics, Inc.
    Via GlobeNewswire
    News headline image
    The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
    From USA News Group
    Via GlobeNewswire
    News headline image
    FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
    From FibroBiologics, Inc.
    Via GlobeNewswire
    News headline image
    FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
    From FibroBiologics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is FibroBiologics, Inc. - Common Stock publicly traded?
    Yes, FibroBiologics, Inc. - Common Stock is publicly traded.
    What exchange does FibroBiologics, Inc. - Common Stock trade on?
    FibroBiologics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for FibroBiologics, Inc. - Common Stock?
    The ticker symbol for FibroBiologics, Inc. - Common Stock is FBLG on the Nasdaq Stock Market
    What is the current price of FibroBiologics, Inc. - Common Stock?
    The current price of FibroBiologics, Inc. - Common Stock is 1.100
    When was FibroBiologics, Inc. - Common Stock last traded?
    The last trade of FibroBiologics, Inc. - Common Stock was at 06/03/26 11:16 AM ET
    What is the market capitalization of FibroBiologics, Inc. - Common Stock?
    The market capitalization of FibroBiologics, Inc. - Common Stock is 42.09M
    How many shares of FibroBiologics, Inc. - Common Stock are outstanding?
    FibroBiologics, Inc. - Common Stock has 42M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.